National Research Corporation
NASDAQ:NRCMedical - Healthcare Information Services
+$0.07 today
- Market cap
- $555.16M
- Beta
- 0.40
- P/E (TTM)
- 43.0
- EPS (TTM)
- $0.41
- Dividend yield
- 3.14%
Volume 0.09M
Average 0.11M
NRC Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
National Research CorporationNASDAQ: NRC
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q1 FY2026 stock-based compensation of $1.61M rose 840.4% year over year, behind the +867.2% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 15.8% from the prior quarter. Over 3 fiscal years it compounded at +40.3% a year.
Context
- Stock-based compensation amounted to 2.4% of revenue in FY2025, up 2.2 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +840.4% toward the trailing-twelve-month pace of +867.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 3.31M USD
- Year-over-year change
- +1066.2%
- 4-year CAGR
- +51.8%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.31M | +1066.2% |
| FY2024 | 2024-12-31 | 284K | -69.6% |
| FY2023 | 2023-12-31 | 935K | -22.1% |
| FY2022 | 2022-12-31 | 1.2M | +92.6% |
| FY2021 | 2021-12-31 | 623K | — |
Stock-Based Compensation vs competitors
How NRC compares with its peers on the latest reported figures
- NRC's LTM Mar 2026 stock-based compensation of $4.75M is the 7th largest of the 8 companies compared; the peer median is $19.47M.
- Its year-over-year change of +867.2% is the highest of 8, against a peer median of -9.3%.
- Stock-based compensation amounts to 3.4% of revenue for NRC, versus a peer median of 6.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | $63.78M | -5.3% | +4.7% | 12.9% | |
CTEVClaritev Corporation | LTM Mar 2026 | $28.39M | +2.6% | +18.5% | 2.9% |
| LTM Mar 2026 | $27.05M | -9.3% | -7.2% | 11.4% | |
| LTM Mar 2026 | $19.47M | -47.1% | -27.9% | 6.4% | |
| LTM Mar 2026 | $8.5M | -48.8% | — | 10.5% | |
| LTM Mar 2026 | $8.35M | +85.0% | +31.8% | 2.7% | |
| LTM Mar 2026 | $4.75M | +867.2% | +40.3% | 3.4% | |
| LTM Mar 2026 | $67K | -92.8% | -54.8% | 0.1% | |
| Peer median (excluding NRC) | $19.47M | -9.3% | -1.2% | 6.4% | |
Competitors are the stored peer set for NRC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 37.47M | 31.8M | 30.97M | 24.78M | 11.6M |
| Depreciation & Amortization | 6.37M | 5.28M | 5.9M | 6.02M | 7.62M |
| Deferred Income Tax | 33K | (1.24M) | (717K) | (406K) | 2.45M |
| Stock-Based Compensation | 623K | 1.2M | 935K | 284K | 3.31M |
| Change in Working Capital | 1.84M | (3.35M) | 1.03M | 3.84M | 916K |
| Accounts Receivables | 343K | (733K) | 2.08M | 1.76M | (53K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 4K | (589K) | 184K | (108K) | 170K |
| Other Working Capital | 1.49M | (2.03M) | (1.24M) | 2.19M | 799K |
| Other Non-Cash Items | 7K | 2.58M | (102K) | 100K | 545K |
| Operating Cash Flow | 46.34M | 36.27M | 38.11M | 34.63M | 26.45M |
| Capital Expenditures | (5.51M) | (9.84M) | (15.78M) | (15.45M) | (10.71M) |
| Acquisitions (Net) | (3M) | 0 | 0 | (4.83M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 1K | 0 | 0 |
| Investing Cash Flow | (8.51M) | (9.84M) | (15.78M) | (20.28M) | (10.71M) |
| Debt Repayment | (4.59M) | (4.77M) | 14.18M | 25.99M | 16.11M |
| Common Stock Issued | 0 | 0 | 0 | 0 | 132K |
| Common Stock Repurchased | (4.14M) | (27.62M) | (19.1M) | (30.95M) | (20.18M) |
| Dividends Paid | (9.16M) | (20.96M) | (36.37M) | (11.45M) | (10.98M) |
| Other Financing Activities | (275K) | (2.04M) | 576K | (359K) | (923K) |
| Financing Cash Flow | (18.16M) | (55.58M) | (40.71M) | (16.76M) | (15.84M) |
| Effect of Forex Changes | 3K | (182K) | (1K) | 0 | 0 |
| Net Change in Cash | 19.67M | (29.34M) | (18.37M) | (2.42M) | (94K) |
| Free Cash Flow | 40.83M | 26.43M | 22.33M | 19.18M | 15.74M |
National Research Corporation
NASDAQ:NRC
Intrinsic Alpha fair value
Locked
Current Price
$26.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.